{"paper_id": "0f512cc78158081683957d611cf8421ba1f9dc04", "metadata": {"title": "", "authors": []}, "abstract": [], "body_text": [{"text": "Non-life threatening and could be deferred 6-8 weeks during the COVID-19 pandemic C Stable even in the discontinuation of treatment during the current COVID-19 crisis COVID-19, coronavirus disease 2019. Immediate management of toxicity should be required as soon as possible even in the circumstances of COVID-19 pandemic B Neutropenia Administration of hematologic growth factor is recommended as quickly as possible COVID-19, coronavirus disease 2019; CCRT, concurrent chemo-radiation treatment; EBRT, external beam radiation therapy; LLETZ, large loop excision of the transformation zone. ", "cite_spans": [], "ref_spans": [], "section": "Recommendations for gynecologic cancer care during the COVID-19 pandemic"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "Clinical characteristics of coronavirus disease 2019 in China", "authors": [{"first": "W", "middle": ["J"], "last": "Guan", "suffix": ""}, {"first": "Z", "middle": ["Y"], "last": "Ni", "suffix": ""}, {"first": "Y", "middle": [], "last": "Hu", "suffix": ""}, {"first": "W", "middle": ["H"], "last": "Liang", "suffix": ""}, {"first": "C", "middle": ["Q"], "last": "Ou", "suffix": ""}, {"first": "J", "middle": ["X"], "last": "He", "suffix": ""}], "year": 2020, "venue": "N Engl J Med", "volume": "382", "issn": "", "pages": "1708--1728", "other_ids": {}}, "BIBREF2": {"ref_id": "b2", "title": "World Health Organization. Coronavirus disease (COVID-19) pandemic [Internet]. Geneva: World Health Organization; c2020", "authors": [], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF3": {"ref_id": "b3", "title": "COVID-19 dashboard by the center for systems science and engineering at Johns Hopkins University", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF4": {"ref_id": "b4", "title": "Johns Hopkins University; c2020", "authors": [{"first": "M", "middle": ["D"], "last": "Baltimore", "suffix": ""}], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF5": {"ref_id": "b5", "title": "Recommendations for prioritization, treatment and triage of breast cancer patients during the COVID-19 pandemic: executive summary", "authors": [], "year": 2020, "venue": "The COVID-19 Pandemic Breast Cancer Consortium", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF6": {"ref_id": "b6", "title": "Pandemic planning clinical guideline for patients with cancer", "authors": [], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF7": {"ref_id": "b7", "title": "National Comprehensive Cancer Network. COVID-19 resources", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF8": {"ref_id": "b8", "title": "PA: National Comprehensive Cancer Network; c2020", "authors": [], "year": 2020, "venue": "Plymouth Meeting", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF10": {"ref_id": "b10", "title": "ASCCP interim guidance for timing of diagnostic and treatment procedures for patients with abnormal cervical screening tests", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF11": {"ref_id": "b11", "title": "American Society for Colposcopy and Cervical Pathology; c2020", "authors": [], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF12": {"ref_id": "b12", "title": "Cancer patient management during the COVID-19 pandemic", "authors": [], "year": 2020, "venue": "European Society for Medical Oncology (ESMO)", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF13": {"ref_id": "b13", "title": "The impact of waiting intervals on survival outcomes of patients with endometrial cancer: a systematic review of the literature", "authors": [{"first": "V", "middle": [], "last": "Pergialiotis", "suffix": ""}, {"first": "D", "middle": [], "last": "Haidopoulos", "suffix": ""}, {"first": "A", "middle": ["S"], "last": "Tzortzis", "suffix": ""}, {"first": "I", "middle": [], "last": "Antonopoulos", "suffix": ""}, {"first": "N", "middle": [], "last": "Thomakos", "suffix": ""}, {"first": "A", "middle": [], "last": "Rodolakis", "suffix": ""}], "year": 2020, "venue": "Eur J Obstet Gynecol Reprod Biol", "volume": "246", "issn": "", "pages": "1--6", "other_ids": {}}, "BIBREF16": {"ref_id": "b16", "title": "BSGE and BGCS guidance for the management of abnormal uterine bleeding in the evolving coronavirus (COVID-19) pandemic. London: Royal College of Obstetricians & Gynaecologists", "authors": [], "year": 2020, "venue": "British Gynaecological Cancer Society. Joint RCOG", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF17": {"ref_id": "b17", "title": "COVID-19 resources", "authors": [], "year": null, "venue": "Society of Gynecologic Oncology", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF18": {"ref_id": "b18", "title": "Society of Gynecologic Oncology; c2020", "authors": [], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF19": {"ref_id": "b19", "title": "Management of uterine cancer during the COVID-19 pandemic", "authors": [], "year": 2020, "venue": "European Society of Gynaecological Oncology", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF20": {"ref_id": "b20", "title": "COVID-19 global pandemic: options for management of gynecologic cancers", "authors": [{"first": "P", "middle": ["T"], "last": "Ramirez", "suffix": ""}, {"first": "L", "middle": [], "last": "Chiva", "suffix": ""}, {"first": "A", "middle": ["G"], "last": "Eriksson", "suffix": ""}, {"first": "M", "middle": [], "last": "Frumovitz", "suffix": ""}, {"first": "A", "middle": [], "last": "Fagotti", "suffix": ""}, {"first": "Gonzalez", "middle": [], "last": "Martin", "suffix": ""}, {"first": "A", "middle": [], "last": "", "suffix": ""}], "year": 2020, "venue": "Int J Gynecol Cancer", "volume": "30", "issn": "", "pages": "561--564", "other_ids": {}}, "BIBREF22": {"ref_id": "b22", "title": "COVID-19 resources", "authors": [], "year": null, "venue": "Society of Gynecologic Oncology", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF23": {"ref_id": "b23", "title": "Society of Gynecologic Oncology; c2020", "authors": [], "year": 2020, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF24": {"ref_id": "b24", "title": "Recommendations for the surgical management of gynecological cancers during the COVID-19 pandemic -FRANCOGYN group for the CNGOF", "authors": [{"first": "C", "middle": [], "last": "Akladios", "suffix": ""}, {"first": "H", "middle": [], "last": "Azais", "suffix": ""}, {"first": "M", "middle": [], "last": "Ballester", "suffix": ""}, {"first": "S", "middle": [], "last": "Bendifallah", "suffix": ""}, {"first": "P", "middle": ["A"], "last": "Bolze", "suffix": ""}, {"first": "N", "middle": [], "last": "Bourdel", "suffix": ""}], "year": null, "venue": "J Gynecol Obstet Hum Reprod", "volume": "2020", "issn": "", "pages": "", "other_ids": {}}}, "ref_entries": {"TABREF0": {"text": "The classification of priorities according to the severity of disease condition", "latex": null, "type": "table", "html": "<html><body><table><tr><td>\u00a0</td><td> Recommendations for cervical cancer care during the COVID-19 pandemic\n</td></tr><tr><td>Priority </td><td>Patient's status </td><td>Management\n</td></tr><tr><td>New diagnosis or screening test\n</td><td>\u00a0</td></tr><tr><td>A </td><td>Massive and/or persistent bleeding from cervix\n</td><td>Assessment should be performed as soon as possible based on the level of institution resources or regional circumstances of COVID-19\n</td></tr><tr><td>C </td><td>Routine screening </td><td>It is preferable to discontinue all routine check-up during COVID-19 pandemic or consider to refer to the accessible local clinic\n</td></tr><tr><td>B </td><td>Abnormal Pap result\nSuspected of low-grade cervical disease </td><td>Assessment could be deferred up to 6-12 months\n</td></tr><tr><td>B </td><td>Suspected of high-grade cervical disease without invasive cancer\n</td><td>It is appropriate to evaluate lesions within 3 months\n</td></tr><tr><td>B </td><td>Suspected of invasive cervical cancer </td><td>Diagnosis of the lesion could be prioritized within 2 weeks\n</td></tr><tr><td>Early-stage cervical cancer\n</td><td>\u00a0</td></tr><tr><td>C </td><td>Stage IA1 based on LLETZ pathology </td><td>It might be possible to observe the lesion without further treatment until COVID-19 outbreak wanes\n</td></tr><tr><td>B </td><td>Stage IA2 based on LLETZ pathology </td><td>It could be postponed to perform further treatment up to 6-8 weeks\n</td></tr><tr><td>B </td><td>Stage IB1, IB2, and IIA1 </td><td>Radical hysterectomy can be postponed up to 6-8 weeks and can be replaced by alternatives such as trachelectomy, neoadjuvant chemotherapy, or radiation therapy in consideration of fertility </td></tr><tr><td>C </td><td>Postoperative status - low risk of recurrence </td><td>preservation, operation morbidity, and patient condition\nAdjuvant therapy might be discontinued during the crisis of COVID-19\n</td></tr><tr><td>B </td><td>Postoperative status - intermediate risk of recurrence\n</td><td>(CC)RT can be deferred up to 8 weeks after surgery in consideration of risk of Sedlis criteria\n</td></tr><tr><td>B </td><td>Postoperative status - high risk of </td><td>It is preferable to perform CCRT on schedule\n</td></tr><tr><td>B </td><td>recurrence\nStage IB3, and IIA2 </td><td>It is appropriate to perform EBRT using hypofractionation to reduce the number of visit to clinic. </td></tr><tr><td>B </td><td>Locally advanced cervical cancer (IIB- IVA) </td><td>Radical hysterectomy can be chosen on the decision of physician.\nCCRT is recommended on schedule, and could consider hypofractionation to reduce the number of visit to clinic. Brachytherapy should be done on time unless there is COVID-19 symptom.\n</td></tr><tr><td>B </td><td>Stage IVB cervical cancer </td><td>It is preferable to perform chemotherapy consisting of cisplatin and paclitaxel, (+/\u2212) bevacizumab on schedule.\n</td></tr><tr><td>Recurrent cervical cancer\n</td><td>\u00a0</td></tr><tr><td>B </td><td>Cervical stump recurrence </td><td>Surgical resection or radiation therapy can be considered according to the level of institutional resources on schedule\n</td></tr><tr><td>B B </td><td>Vaginal recurrence with bleeding Local recurrence within pelvis </td><td>It is recommended to perform brachytherapy or EBRT on schedule\n(CC)RT is recommended on schedule, and could consider hypofractionation to reduce the number </td></tr><tr><td>B </td><td>Distant recurrence - chest only </td><td>of visit to clinic. Brachytherapy should be done on time unless there is COVID-19 symptom.\nChemotherapy is recommended on schedule, but it can be deferred for several week in case of no adverse effect caused by the delay of treatment\n</td></tr><tr><td>B </td><td>Distant multiple recurrence </td><td>Chemotherapy is recommended on schedule, but it can be deferred for several week in case of no adverse effect caused by the delay of treatment\n</td></tr><tr><td>B </td><td>Pelvic side wall recurrence </td><td>Ultra-radical surgery or radiation could be recommended according to the level of institution resources\n</td></tr><tr><td>Follow-up\n</td><td>\u00a0</td></tr><tr><td>C </td><td>Follow-up after curative operation </td><td>Surveillance can be deferred based on the level of risk for recurrence\n</td></tr><tr><td>C </td><td>Follow-up after curative radiation Special situation\n</td><td>Surveillance can be deferred based on the level of risk for recurrence\n</td></tr><tr><td>B </td><td>Occult cervical cancer after simple hysterectomy\n</td><td>The treatment can be chosen among observation, surgery, or radiation after pathologic review. It can be deferred for several week in case of no adverse effect caused by delay of treatment\n</td></tr><tr><td>C </td><td>Condition requiring palliative treatment </td><td>The treatment can be postponed after consultation with multidisciplinary team\n</td></tr><tr><td>A </td><td>Serious toxicity (i.e. fever, pain, dyspnea, bowel perforation, and unstable vital sign)\n</td><td>Immediate management of toxicity should be required as soon as possible even in the circumstances of COVID-19 pandemic\n</td></tr><tr><td>B </td><td>Neutropenia </td><td>Administration of hematologic growth factor is recommended as quickly as possible\nCOVID-19, coronavirus disease 2019; CCRT, concurrent chemo-radiation treatment; EBRT, external beam radiation therapy; LLETZ, large loop excision of the </td></tr></table></body></html>"}, "TABREF1": {"text": "Recommendations for cervical cancer care during the COVID-19 pandemic", "latex": null, "type": "table"}, "TABREF2": {"text": "Recommendations for endometrial cancer care during the COVID-19 pandemicIn case of clinically significant AUB, office-based endometrial biopsy should be performed in outpatient setting based on the level of institution resources or regional circumstances of COVID-19 In case of pelvic RT, consider hypofractionation to reduce the number of visit to clinic. BSurgical stage IVA Depending on the discretion of the physician, adjuvant chemotherapy or radiotherapy is considered. Use chemotherapy regimens that will avoid frequent patient visits (e.g. paclitaxel + carboplatin).In case of pelvic RT, consider hypofractionation to reduce the number of visit to clinic.", "latex": null, "type": "table"}, "TABREF3": {"text": "Recommendations grade serous with BRCA mutation In patients who have a BRCA mutation and are PARP na\u00efve, consider rucaparib monotherapy in situations where platinum therapy cannot be given. B Clear cell or mucinous tumor Adjuvant chemotherapy can be an option, but should be considered less essential and discussed with the patient about minimizing the infusion visits. C Low-grade serous tumor Consider deferring the adjuvant therapy as possible. C After upfront adjuvant chemotherapy Consider deferring the maintenance chemotherapy as possible. If utilizing PARPi maintenance therapy, consider the risk of the immunosuppression and exposure to COVID-19 during infusion. Follow-up visit Routine surveillance of asymptomatic patients should be postponed as possible. Utilize telemedicine and reduce the frequency of in-person evaluation. C Patients with PARPi maintenance Most can be managed through telemedicine with scheduled blood tests and imaging done close to home. C Patients with bevacizumab maintenance If facilities exist to continue, supervision can be performed by telemedicine, ensuring BP and urinalysis are monitored. Recurrent disease Choice of therapy should minimize exposure to other contacts, risk from therapy, and prognosis. B Symptomatic platinum-sensitive recurrent disease Adjuvant chemotherapy can be an option, but should be considered less essential and discussed with the patient about minimizing the infusion visits. C Symptomatic platinum-resistant recurrent disease Non platinum-based regimen are low priority and should be used after careful review of the risk/ benefit. C Symptomatic slowly growing recurrent disease Decision should be based on clinical judgement. C Asymptomatic recurrent disease Decision should be based on clinical judgement. Special situation C Risk-reducing salpingo-oophorectomy for genetic predisposition to gynecological cancer Consider deferring the surgery as possible. COVID-19, coronavirus disease 2019; BRCA, breast cancer gene; BP, blood pressure; HIPEC, hyperthermic intraperitoneal chemotherapy; PARPi, poly ADP ribose polymerase inhibitor.", "latex": null, "type": "table"}}, "back_matter": []}